US Patent

US8410169 — Compounds and methods for delivery of prostacyclin analogs

Formulation · Assigned to United Therapeutics Corp · Expires 2030-02-13 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods and compounds that increase the oral bioavailability and circulating concentrations of treprostinil diolamine.

USPTO Abstract

This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula:

Drugs covered by this patent

Patent Metadata

Patent number
US8410169
Jurisdiction
US
Classification
Formulation
Expires
2030-02-13
Drug substance claim
No
Drug product claim
Yes
Assignee
United Therapeutics Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.